Premium
Kinetics of Anti‐Mannan Antibodies Useful in Confirming Invasive Candidiasis in Immunocompromised Patients
Author(s) -
Deventer A. Johanna M.,
Goessens Wil H.F.,
Zeijl Jan H.,
Mouton Jan W.,
Michel Marc F.,
Verbrugh Henri A.
Publication year - 1996
Publication title -
microbiology and immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.664
H-Index - 70
eISSN - 1348-0421
pISSN - 0385-5600
DOI - 10.1111/j.1348-0421.1996.tb03327.x
Subject(s) - mannan , invasive candidiasis , candida albicans , antibody , biology , titer , immunology , corpus albicans , antibody titer , microbiology and biotechnology , fluconazole , antifungal , polysaccharide , biochemistry
In studying the anti‐mannan antibodies longitudinally in serial serum samples of three immunocompromised patients, it was observed that anti‐mannan antibodies started to increase shortly after the moment that cultures of deep‐tissue sites became positive with Candida albicans . The mean anti‐mannan antibody titers determined in a group of 36 immunocompromised patients with invasive candidiasis increased within two weeks after the probable onset of invasive candidiasis. In contrast, anti‐mannan antibody levels in serial serum samples of 14 immunocompromised patients who were only colonized with C. albicans remained stable or decreased over time. The HA test measuring the anti‐mannan antibodies was 64% sensitive and 89% specific in determining invasive candidiasis. In contrast, antibodies specific for candidal cytoplasmic antigens or enolase alone were of little value in confirming invasive candidiasis in these immunocompromised patients.